ATE186218T1 - Impfstoffzusammensetzungen fuer mukosale abgabe - Google Patents

Impfstoffzusammensetzungen fuer mukosale abgabe

Info

Publication number
ATE186218T1
ATE186218T1 AT93911878T AT93911878T ATE186218T1 AT E186218 T1 ATE186218 T1 AT E186218T1 AT 93911878 T AT93911878 T AT 93911878T AT 93911878 T AT93911878 T AT 93911878T AT E186218 T1 ATE186218 T1 AT E186218T1
Authority
AT
Austria
Prior art keywords
vaccine compositions
tetanus
mucosal surface
provides
pertussis
Prior art date
Application number
AT93911878T
Other languages
English (en)
Inventor
Mark Roberts
Gordon Dougan
Medicine Technology
Original Assignee
Medeva Holdings Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medeva Holdings Bv filed Critical Medeva Holdings Bv
Application granted granted Critical
Publication of ATE186218T1 publication Critical patent/ATE186218T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT93911878T 1992-04-28 1993-04-28 Impfstoffzusammensetzungen fuer mukosale abgabe ATE186218T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929209118A GB9209118D0 (en) 1992-04-28 1992-04-28 Vaccine compositions

Publications (1)

Publication Number Publication Date
ATE186218T1 true ATE186218T1 (de) 1999-11-15

Family

ID=10714652

Family Applications (2)

Application Number Title Priority Date Filing Date
AT98120803T ATE340589T1 (de) 1992-04-28 1993-04-28 Impfstoffzusammensetzungen für mukosale abgabe
AT93911878T ATE186218T1 (de) 1992-04-28 1993-04-28 Impfstoffzusammensetzungen fuer mukosale abgabe

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT98120803T ATE340589T1 (de) 1992-04-28 1993-04-28 Impfstoffzusammensetzungen für mukosale abgabe

Country Status (11)

Country Link
US (1) US6562352B1 (de)
EP (2) EP0639081B1 (de)
AT (2) ATE340589T1 (de)
AU (1) AU4267093A (de)
DE (2) DE69326948T2 (de)
DK (2) DK0937462T3 (de)
ES (2) ES2141765T3 (de)
GB (1) GB9209118D0 (de)
GR (1) GR3032381T3 (de)
PT (2) PT937462E (de)
WO (1) WO1993021950A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197548B1 (en) 1990-04-02 2001-03-06 Medeva Pharma Limited Transformed Pichia expressing the pertactin antigen
US7214787B1 (en) * 1993-09-21 2007-05-08 United States Of America As Represented By The Secretary Of The Army Recombinant vaccine against botulinum neurotoxin
WO1997002835A1 (en) * 1995-07-07 1997-01-30 Oravax, Inc. Intranasal vaccination against gastrointestinal disease
GB9611501D0 (en) * 1996-06-03 1996-08-07 Smithkline Beecham Biolog Vaccine compositions
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
CA2341358C (en) * 1998-09-01 2011-04-26 David James Brayden Method for inducing a cell-mediated immune response and parenteral vaccine formulations therefor
AU5441199A (en) * 1998-09-01 2000-03-21 Elan Corporation, Plc Oral vaccine compositions
US7087236B1 (en) 1998-09-01 2006-08-08 Merrion Research I Limited Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
GB9923060D0 (en) * 1999-09-29 1999-12-01 Chiron Spa Vaccine
US6651655B1 (en) 2000-01-18 2003-11-25 Quadrant Technologies Limited Inhaled vaccines
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
BR0214279A (pt) * 2001-11-19 2005-12-20 Becton Dickinson Co Composições farmacêuticas em forma particulada
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
US8916165B2 (en) 2004-12-15 2014-12-23 Janssen Alzheimer Immunotherapy Humanized Aβ antibodies for use in improving cognition
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
PL2182983T3 (pl) 2007-07-27 2014-10-31 Janssen Alzheimer Immunotherap Leczenie chorób amyloidowych z wykorzystaniem humanizowanych przeciwciał specyficznych względem Abeta
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8516442D0 (en) * 1985-06-28 1985-07-31 Wellcome Found Cloned antigen
JPS632932A (ja) * 1986-06-23 1988-01-07 Teijin Ltd 経鼻投与用粉末状組成物
EP0267998A1 (de) 1986-11-17 1988-05-25 Institut Pasteur Mittel zur Unterstützung gegen Infektion und Vergiftung von Bordetella
GB8910570D0 (en) * 1989-05-08 1989-06-21 Wellcome Found Acellular vaccine
GB8914122D0 (en) * 1989-06-20 1989-08-09 Wellcome Found Polypeptide expression
IT1248735B (it) * 1990-06-21 1995-01-26 Sclavo Spa Vaccini acellulari contro la pertosse
EP0484621A3 (en) * 1990-07-11 1992-08-26 American Cyanamid Company Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens
PL170938B1 (pl) * 1991-03-05 1997-02-28 Wellcome Found Sposób wytwarzania szczepionki przeciwko infekcjom Salmonella PL PL
WO2006034129A2 (en) * 2004-09-17 2006-03-30 Jmar Research, Inc. Systems and methods for detecting scattered light from a particle using illumination incident at an angle

Also Published As

Publication number Publication date
DK0639081T3 (da) 2000-04-10
PT639081E (pt) 2000-04-28
DE69326948T2 (de) 2000-03-16
DE69334066D1 (de) 2006-11-09
GR3032381T3 (en) 2000-04-27
EP0937462A1 (de) 1999-08-25
DE69326948D1 (de) 1999-12-09
EP0937462B1 (de) 2006-09-27
EP0639081B1 (de) 1999-11-03
AU4267093A (en) 1993-11-29
EP0639081A1 (de) 1995-02-22
WO1993021950A1 (en) 1993-11-11
PT937462E (pt) 2007-01-31
ES2273391T3 (es) 2007-05-01
GB9209118D0 (en) 1992-06-10
DE69334066T2 (de) 2007-05-03
DK0937462T3 (da) 2007-01-29
ATE340589T1 (de) 2006-10-15
ES2141765T3 (es) 2000-04-01
US6562352B1 (en) 2003-05-13

Similar Documents

Publication Publication Date Title
DE69326948D1 (de) Impfstoffzusammensetzungen fuer mukosale abgabe
JP3911058B2 (ja) ストレプトコックス エキワクチン
FR16C0015I2 (fr) Vaccins anticoquelucheux acellulaires et procedes de preparation correspondants
FI101632B1 (fi) Menetelmä Bordetella pertussis-toksiinin alayksikön analogien valmistamiseksi ja niitä koodaavia rekombinantti-DNA-molekyylejä
LU90203I2 (fr) Anatoxine diphtérique anatoxine tétanique trois antigènes coquelucheux purifiés (toxine pertussique tp hémagglutinine filamenteuse (haf) et pertactine (protéine de membrane externe 69 kd) et le principal antigène de surface du virus de l'hépatite b (vhb) purfié (infanrix hepb) et ses dérivés pharmaceutiquement acceptables
LU91149I2 (fr) Combinaison d'anatoxine diphtérique, d'anatoxine tétanique, d'anatoxine coquelucheuse, d'hémagglutinine filamenteuse, de pertactine et d'antigène de surface recombinant du virus d l'hépatite B(protéine S).
CY1110327T1 (el) DTPa ΕΜΒΟΛΙΑ ΒΛΕΝΝΟΓΟΝΟΥ
DK0725653T3 (da) Vaccinepræparater
EP1123711B1 (de) Attenuierte Toxine als Adjuvantien
ATE258445T1 (de) Impfstoff beinhaltend bacterin und toxoid aus pasteurella haemolytica typ a-1
EP1490100B1 (de) Kombinierte dns/protein impfstoffzusammensetzungen
RU2185852C1 (ru) Способ вакцинопрофилактики дифтерии и столбняка на крайнем севере
WO1997046255A3 (en) Vaccine composition comprising outer membrane protein fragments of bordetella pertussis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee